Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sulbactam + durlobactam + meropenem
- Development stage
- Preclinical
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Xacduro + meropenem is a co-administration regimen combining Xacduro (sulbactam-durlobactam), a novel beta-lactam/beta-lactamase inhibitor, with meropenem, an ultra-broad-spectrum carbapenem antibiotic. Developed by Innoviva (via its subsidiary Entasis Therapeutics) and Pfizer/Sumitomo Pharma respectively, this combination is primarily utilized for the treatment of severe, invasive infections caused by carbapenem-resistant *Acinetobacter baumannii-calcoaceticus* complex (CRAB), such as hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP). Sulbactam acts as a beta-lactam antibiotic with intrinsic activity against *A. baumannii* by targeting penicillin-binding proteins (PBPs), specifically PBP1 and PBP3. Durlobactam is a diazabicyclooctane beta-lactamase inhibitor that potently inhibits Ambler Class A, C, and D serine beta-lactamases (including OXA-type carbapenemases), thereby restoring sulbactam's bactericidal activity. Meropenem, a carbapenem that inhibits cell wall synthesis by binding to PBPs, is co-administered to provide synergistic antibacterial activity and expand coverage against polymicrobial infections. This combination is recommended by the Infectious Diseases Society of America (IDSA) as a preferred therapeutic strategy for moderate-to-severe CRAB infections.
- Other names
- SUL-DUR + meropenemSUL/DUR + meropenemsulbactam + durlobactam + meropenemsulbactam-durlobactam + meropenemXacduro + MerremXacduro + meropenem
02
Targets
β-lactamasePBP1 (Penicillin-binding protein 1)PBP2 (Penicillin-binding protein 2)PBP4 (Penicillin-binding protein 4)
Beyond the preview
Go deeper on sulbactam + durlobactam + meropenem.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sulbactam + durlobactam + meropenem.